PPARγ Agonists as an Anti-Inflammatory Treatment Inhibiting Rotavirus Infection of Small Intestinal Villi

Figure 3

Expression of cellular proteins in villus cells from in vivo and in vitro ECwt-infected villi after treatment with PGZ. (a) Villi isolated from ECwt-infected mice ( per experiment) treated or not with PGZ were processed for immunofluorescence analysis using the primary antibodies against the indicated cellular proteins. Data are presented as mean percentage of villus cells being positive to the indicated proteins. (b) Villi isolated from ECwt-infected mice ( per experiment) treated or not with PGZ during the period 12 to 48 h.p.i. were lysed and analyzed by capture ELISA using detecting antibodies against the indicated proteins. Data are shown as mean values through the indicated period. (c) Villi isolated from mice were infected in vitro with ECwt and then treated or not with PGZ before being subjected to immunofluorescence analysis as indicated in (a). (d) Villi isolated from mice were infected in vitro with ECwt and treated or not with PGZ before being analyzed by ELISA as indicated in (b). (e) Villi isolated from mice were infected in vitro with ECwt, treated or not as indicated in (e), and analyzed by ELISA as indicated in (b). Results are presented as mean ± SD from three independent experiments performed in duplicate. (f) Villi isolated from mice were infected or not in vitro with ECwt and treated or not with PGZ before Western blotting analysis of villus lysates for the expression of PPARγ. (g) Villi isolated from mice were infected or not in vitro with ECwt and treated or not with RGZ, TZD, ALA, DHA, and ATRA before Western blotting analysis using anti-PPARγ and anti-NF-κB antibodies.

(a)

(b)

(c)

(d)

(e)

(f)

(g)